Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 26

1.

Broad Cytotoxic Targeting of Acute Myeloid Leukemia by Polyclonal Delta One T Cells.

Di Lorenzo B, Simões AE, Caiado F, Tieppo P, Correia DV, Carvalho T, da Silva MG, Déchanet-Merville J, Schumacher TN, Prinz I, Norell H, Ravens S, Vermijlen D, Silva-Santos B.

Cancer Immunol Res. 2019 Apr;7(4):552-558. doi: 10.1158/2326-6066.CIR-18-0647. Epub 2019 Mar 20.

PMID:
30894378
2.

Evaluating in vivo efficacy - toxicity profile of TEG001 in humanized mice xenografts against primary human AML disease and healthy hematopoietic cells.

Johanna I, Straetemans T, Heijhuurs S, Aarts-Riemens T, Norell H, Bongiovanni L, de Bruin A, Sebestyen Z, Kuball J.

J Immunother Cancer. 2019 Mar 12;7(1):69. doi: 10.1186/s40425-019-0558-4.

3.

Low-Density Lipoprotein Uptake Inhibits the Activation and Antitumor Functions of Human Vγ9Vδ2 T Cells.

Rodrigues NV, Correia DV, Mensurado S, Nóbrega-Pereira S, deBarros A, Kyle-Cezar F, Tutt A, Hayday AC, Norell H, Silva-Santos B, Dias S.

Cancer Immunol Res. 2018 Apr;6(4):448-457. doi: 10.1158/2326-6066.CIR-17-0327. Epub 2018 Jan 22.

4.

VEGFR2-Mediated Reprogramming of Mitochondrial Metabolism Regulates the Sensitivity of Acute Myeloid Leukemia to Chemotherapy.

Nóbrega-Pereira S, Caiado F, Carvalho T, Matias I, Graça G, Gonçalves LG, Silva-Santos B, Norell H, Dias S.

Cancer Res. 2018 Feb 1;78(3):731-741. doi: 10.1158/0008-5472.CAN-17-1166. Epub 2017 Dec 11.

5.

Intra-tumour heterogeneity - going beyond genetics.

Caiado F, Silva-Santos B, Norell H.

FEBS J. 2016 Jun;283(12):2245-58. doi: 10.1111/febs.13705. Epub 2016 Apr 1. Review.

6.

γδ T cells in cancer.

Silva-Santos B, Serre K, Norell H.

Nat Rev Immunol. 2015 Nov;15(11):683-91. doi: 10.1038/nri3904. Epub 2015 Oct 9. Review.

PMID:
26449179
7.

At the Bench: Preclinical rationale for exploiting NK cells and γδ T lymphocytes for the treatment of high-risk leukemias.

Norell H, Moretta A, Silva-Santos B, Moretta L.

J Leukoc Biol. 2013 Dec;94(6):1123-39. doi: 10.1189/jlb.0613312. Epub 2013 Oct 9. Review.

PMID:
24108703
8.

A coreceptor-independent transgenic human TCR mediates anti-tumor and anti-self immunity in mice.

Mehrotra S, Al-Khami AA, Klarquist J, Husain S, Naga O, Eby JM, Murali AK, Lyons GE, Li M, Spivey ND, Norell H, Martins da Palma T, Onicescu G, Diaz-Montero CM, Garrett-Mayer E, Cole DJ, Le Poole IC, Nishimura MI.

J Immunol. 2012 Aug 15;189(4):1627-38. doi: 10.4049/jimmunol.1103271. Epub 2012 Jul 13.

9.

Off-target function of the Sonic hedgehog inhibitor cyclopamine in mediating apoptosis via nitric oxide-dependent neutral sphingomyelinase 2/ceramide induction.

Meyers-Needham M, Lewis JA, Gencer S, Sentelle RD, Saddoughi SA, Clarke CJ, Hannun YA, Norell H, da Palma TM, Nishimura M, Kraveka JM, Khavandgar Z, Murshed M, Cevik MO, Ogretmen B.

Mol Cancer Ther. 2012 May;11(5):1092-102. doi: 10.1158/1535-7163.MCT-11-0705. Epub 2012 Mar 27.

10.

T cells expanded in presence of IL-15 exhibit increased antioxidant capacity and innate effector molecules.

Kaur N, Naga OS, Norell H, Al-Khami AA, Scheffel MJ, Chakraborty NG, Voelkel-Johnson C, Mukherji B, Mehrotra S.

Cytokine. 2011 Aug;55(2):307-17. doi: 10.1016/j.cyto.2011.04.014. Epub 2011 May 23.

11.

Vaccination with a plasmid DNA encoding HER-2/neu together with low doses of GM-CSF and IL-2 in patients with metastatic breast carcinoma: a pilot clinical trial.

Norell H, Poschke I, Charo J, Wei WZ, Erskine C, Piechocki MP, Knutson KL, Bergh J, Lidbrink E, Kiessling R.

J Transl Med. 2010 Jun 7;8:53. doi: 10.1186/1479-5876-8-53.

12.

CD34-based enrichment of genetically engineered human T cells for clinical use results in dramatically enhanced tumor targeting.

Norell H, Zhang Y, McCracken J, Martins da Palma T, Lesher A, Liu Y, Roszkowski JJ, Temple A, Callender GG, Clay T, Orentas R, Guevara-Patiño J, Nishimura MI.

Cancer Immunol Immunother. 2010 Jun;59(6):851-62. doi: 10.1007/s00262-009-0810-8. Epub 2010 Jan 6.

13.

Primary human tumor cells expressing CD155 impair tumor targeting by down-regulating DNAM-1 on NK cells.

Carlsten M, Norell H, Bryceson YT, Poschke I, Schedvins K, Ljunggren HG, Kiessling R, Malmberg KJ.

J Immunol. 2009 Oct 15;183(8):4921-30. doi: 10.4049/jimmunol.0901226.

14.

Inhibition of superoxide generation upon T-cell receptor engagement rescues Mart-1(27-35)-reactive T cells from activation-induced cell death.

Norell H, Martins da Palma T, Lesher A, Kaur N, Mehrotra M, Naga OS, Spivey N, Olafimihan S, Chakraborty NG, Voelkel-Johnson C, Nishimura MI, Mukherji B, Mehrotra S.

Cancer Res. 2009 Aug 1;69(15):6282-9. doi: 10.1158/0008-5472.CAN-09-1176. Epub 2009 Jul 28.

15.

Transduction with the antioxidant enzyme catalase protects human T cells against oxidative stress.

Ando T, Mimura K, Johansson CC, Hanson MG, Mougiakakos D, Larsson C, Martins da Palma T, Sakurai D, Norell H, Li M, Nishimura MI, Kiessling R.

J Immunol. 2008 Dec 15;181(12):8382-90.

16.

Engineering antigen-specific primary human NK cells against HER-2 positive carcinomas.

Kruschinski A, Moosmann A, Poschke I, Norell H, Chmielewski M, Seliger B, Kiessling R, Blankenstein T, Abken H, Charo J.

Proc Natl Acad Sci U S A. 2008 Nov 11;105(45):17481-6. doi: 10.1073/pnas.0804788105. Epub 2008 Nov 5.

17.

HER-2/neu mediated down-regulation of MHC class I antigen processing prevents CTL-mediated tumor recognition upon DNA vaccination in HLA-A2 transgenic mice.

Vertuani S, Triulzi C, Roos AK, Charo J, Norell H, Lemonnier F, Pisa P, Seliger B, Kiessling R.

Cancer Immunol Immunother. 2009 May;58(5):653-64. doi: 10.1007/s00262-008-0587-1. Epub 2008 Sep 27.

PMID:
18820911
18.

The CD16- CD56(bright) NK cell subset is resistant to reactive oxygen species produced by activated granulocytes and has higher antioxidative capacity than the CD16+ CD56(dim) subset.

Harlin H, Hanson M, Johansson CC, Sakurai D, Poschke I, Norell H, Malmberg KJ, Kiessling R.

J Immunol. 2007 Oct 1;179(7):4513-9.

19.

DNAX accessory molecule-1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells.

Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren HG, Malmberg KJ.

Cancer Res. 2007 Feb 1;67(3):1317-25.

20.

Frequent loss of HLA-A2 expression in metastasizing ovarian carcinomas associated with genomic haplotype loss and HLA-A2-restricted HER-2/neu-specific immunity.

Norell H, Carlsten M, Ohlum T, Malmberg KJ, Masucci G, Schedvins K, Altermann W, Handke D, Atkins D, Seliger B, Kiessling R.

Cancer Res. 2006 Jun 15;66(12):6387-94.

21.

Interferon-gamma renders tumors that express low levels of Her-2/neu sensitive to cytotoxic T cells.

Kaplan BL, Norell H, Callender GG, Ohlum T, Kiessling R, Nishimura MI.

Cancer Immunol Immunother. 2006 Jun;55(6):653-62. Epub 2005 Sep 6.

PMID:
16151808
22.

Detection of human perforin by ELISpot and ELISA: ex vivo identification of virus-specific cells.

Zuber B, Levitsky V, Jönsson G, Paulie S, Samarina A, Grundström S, Metkar S, Norell H, Callender GG, Froelich C, Ahlborg N.

J Immunol Methods. 2005 Jul;302(1-2):13-25.

PMID:
16005014
23.

Preferential cell death of CD8+ effector memory (CCR7-CD45RA-) T cells by hydrogen peroxide-induced oxidative stress.

Takahashi A, Hanson MG, Norell HR, Havelka AM, Kono K, Malmberg KJ, Kiessling RV.

J Immunol. 2005 May 15;174(10):6080-7.

24.

IFN-gamma protects short-term ovarian carcinoma cell lines from CTL lysis via a CD94/NKG2A-dependent mechanism.

Malmberg KJ, Levitsky V, Norell H, de Matos CT, Carlsten M, Schedvins K, Rabbani H, Moretta A, Söderström K, Levitskaya J, Kiessling R.

J Clin Invest. 2002 Nov;110(10):1515-23.

25.

Traumatic rupture of the spleen diagnosed by abdominal aortography; report of a case.

NORELL HG.

Acta radiol. 1957 Dec;48(6):449-52. No abstract available.

PMID:
13508328
26.

Supplemental Content

Loading ...
Support Center